论文部分内容阅读
慢性心力衰竭(心衰)病例使用β受体阻断剂目前已获共识。曾被认为禁忌的慢性心衰患者,现在也推荐使用β受体阻断剂。近年来,从轻症~重症的慢性心衰患者,应用β受体阻断剂的适应证在逐渐拓宽,但是必须要对用药适应证、用药类别以及药物副作用加以注意。血浆脑钠肽(brain natriuretic peptide,BNP)的测定是目前日常循环诊疗中不可缺少的检查手段,广泛应用于心脏疾病筛查、心衰程度判定和疗效判定等。如应用得当,诊断敏感性和特异性均高,非医疗人员、患者自身也能够用具体数值表示出可能到达的治疗目标。BNP是一个有潜力的临床指标,缺点是并不能适用于全体病例。本文介绍BNP指标引导心衰治疗时的注意事项以及今后的展望。
The use of β-blockers in patients with chronic heart failure (HF) has now been agreed. Chronic heart failure, once considered contraindicated, now also recommends the use of beta-blockers. In recent years, from mild to severe chronic heart failure patients, the application of β-blockers indications gradually broadened, but must be on the drug indications, drug classes and drug side effects to be noted. The determination of brain natriuretic peptide (BNP) is an indispensable examination method in daily routine diagnosis and treatment. It is widely used in the screening of heart disease, the determination of the degree of heart failure and the determination of curative effect. If used properly, the diagnostic sensitivity and specificity are high, non-medical personnel, patients themselves can also use specific values that may reach the therapeutic goals. BNP is a potential clinical indicator, the disadvantage is that it does not apply to all cases. This article describes the precautions BNP indicators guide heart failure treatment and the future prospects.